What factors drove the changes in Cryoport's revenue and profit?

Did Cryoport beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Cryoport year over year?

What guidance did Cryoport's management provide for the next earnings period?

What were the key takeaways from Cryoport’s earnings call?

What does Cryoport do and what are its main business segments?

What were the key takeaways from Cryoport's earnings call?

What is Cryoport's latest dividend and current dividend yield?

- **Commercial Growth Acceleration**: 2025 commercial cell and gene therapy revenue surged 29% to $33.4 million, now 20% of total revenue.
- **Pipeline Strength**: 86 Phase III trials position Cryoport for future approvals, with 9 expected in 2026.
- **Strategic Leverage**: DHL partnership and AI adoption drive operational efficiency, targeting H2 2026 positive EBITDA.
- **Market Expansion**: New MVE products (e.g., Fusion 800) open underserved markets, supporting 7% segment growth.

**【CEO Summary Section】**
- Cryoport reported 2025 full-year revenue of $176.2 million, exceeding guidance, driven by 29% year-over-year growth in commercial cell and gene therapy revenue (to $33.4 million) and 22% growth in BioStorage/BioServices revenue.
- Management highlighted a spring-loaded pipeline with 86 Phase III and 361 Phase II clinical trials, anticipating 9 new therapy approvals in 2026 and 13 BLA/MAA filings.
- Strategic partnerships with DHL, Cardinal Health, and Parexel were emphasized to enhance global market reach and operational efficiency.
- AI adoption is accelerating internal workflows, reducing manual tasks, and improving operational consistency.

**【CFO Financial Commentary】**
- 2025 adjusted EBITDA improved by $12 million year-over-year, with a focus on cost reduction initiatives.
- MVE segment grew 7% in 2025, driven by new product launches (e.g., Fusion 800 freezer) and integrated monitoring solutions.
- Guidance for 2026 revenue is $190-194 million, reflecting confidence in commercial therapy growth and operational efficiency gains.

**【Q&A Key Highlights】**
- **Commercial Momentum**: 20% of total revenue now来自 commercial therapies, with 20 approved therapies supported, management expects positive adjusted EBITDA in H2 2026.
- **Partnership Integration**: DHL's global scale will enhance APAC/EMEA expansion, while Cardinal Health and Parexel collaborations standardize clinical supply chains.
- **Risks**: Regulatory delays (e.g., FDA approvals) and macroeconomic volatility could impact clinical trial timelines and customer demand.
- **AI Impact**: Generative AI tools are reducing manual processes, with measurable efficiency improvements across operations.

Cryoport, Inc.(CYRX)-20260304-2025 Q4 Earnings call transcript

- **Revenue Momentum**: Q3 2025 revenue up 16% in Life Sciences Services and 15% in Products, with commercial cell therapy support growing 36% YoY.
- **Profitability Near-Term**: Adjusted EBITDA loss of $600K in Q3, targeting positive EBITDA by year-end 2025 and profitability in 2026.
- **Strategic Investments**: $170-174M 2025 revenue guidance reflects cautious macro assumptions but 8-11% YoY growth, with new facilities in Paris and Santa Ana driving long-term margin expansion.
- **Product Innovation**: Launch of SC4/2V/3V cryogenic systems with condition monitoring and IntegriCell cryopreservation services generating early revenue.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue from continuing operations for Q3 2025 was $42.5 million, up 16% YoY in Life Sciences Services and 15% YoY in Life Sciences Products. Commercial cell and gene therapy support grew 36% YoY.
- **New Product Launches**: Introduced next-generation SC4/2V and SC4/3V cryogenic systems with advanced condition monitoring technology. IntegriCell cryopreservation services in Belgium and Texas are generating early revenue.
- **Strategic Investments**: Opened a 55,000 sq. ft. global supply chain center in Paris (scheduled to begin operations in Q4 2025) and plans to consolidate 3 facilities in Santa Ana, CA by mid-2026.
- **Profitability Pathway**: Adjusted EBITDA loss of $600,000 in Q3, with positive EBITDA expected by year-end 2025 and profitability in 2026.

**【CFO Financial Commentary】**
- **Revenue Guidance**: Full-year 2025 revenue updated to $170-174 million (8-11% YoY growth), reflecting cautious macro outlook but strong long-term market position.
- **Cash Flow**: Positive operating cash flow of $2.2 million in Q3, driven by disciplined cost management and deferred capital investments.
- **Margin Targets**: Aiming for 55% gross margin and 30% EBITDA margin as new facilities ramp up utilization.

**【Q&A Highlights】**
- **Guidance Rationale**: Sequential decline in Q4 2025 guidance reflects cautious macro assumptions (e.g., FDA shutdown, tariff impacts) but maintains 8-11% YoY growth.
- **FDA Draft Guidance Impact**: Recent REMS and clinical trial draft guidances may accelerate cell therapy adoption, with 7+ BLA/MAA filings expected in 2025 and 2 new commercial approvals.
- **2026 Outlook**: Life Sciences Products segment expected to stabilize at high single-digit growth, driven by cryogenic system demand and IntegriCell expansion.
- **Margin Leverage**: New facilities in Paris and Santa Ana will drive operating leverage, with EBITDA improving as utilization rates increase.

Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript

- **14% Revenue Growth**: Driven by 21% service revenue increase, 33% commercial therapy support, and 28% BioStorage growth.
- **$200M DHL Deal**: Strategic partnership enhances global logistics, with immediate cash infusion.
- **Product Innovation**: New MVE shippers and 800-seat freezers expand cryogenic capabilities.
- **Clinical Momentum**: 728 trials supported, 20+ new applications, and 1 therapy approval in 2025.
- **Margin Expansion**: Gross margin 47%, targeting >55% long-term; EBITDA improving from -$5.6M to -$0.9M YoY.
- **Share Buybacks**: 1M shares repurchased, reflecting confidence in undervaluation.


**【CEO Summary Section】**
- Total revenue from continuing operations increased 14% year-over-year to $102.3 million, driven by 21% growth in service revenue (54% of total revenue). Commercial cell and gene therapy support revenue rose 33%, while BioStorage/BioServices grew 28%.
- Launched next-generation MVE SC 4/2 and SC 4/3 vapor shippers, and recorded sales of the high-efficiency 800-seat cryogenic storage system.
- Announced strategic partnership with DHL Group, including $200 million cash infusion, enhancing global biologistics capabilities.
- Supported 728 clinical trials (70% of industry total), with 20+ new applications and 1 therapy approval in 2025. Anticipate 3 approvals for label or geographic expansion.
- Noted a $2 million revenue impact from a client temporarily pausing therapy distribution, but reaffirmed full-year guidance.

**【CFO Financial Commentary】**
- Adjusted EBITDA from continuing operations improved to -$0.9 million (vs. -$5.6 million in Q2 2024), with gross margin at 47% (up 260 bps YoY).
- Cash balance of $426 million post-DHL transaction, with $14 million used to repay 2025 convertible notes.
- Reaffirmed 2025 revenue guidance, targeting long-term gross margins >55% and EBITDA margins >30%.

**【Q&A Key Highlights】**
- **MVE Performance**: 8% YoY growth, driven by animal health and APAC sales. Management expects stabilization post-COVID destocking.
- **IntegriCell**: Revenue expected to begin in Q3 2025, with meaningful contributions in 2026. Gross margin target >60% at maturity.
- **Capital Allocation**: Prioritize share buybacks (1M shares repurchased in Q2) and strategic partnerships, with no immediate M&A plans.
- **FDA Impact**: Positive response to REMS updates, but 5 clients received FDA negative opinions, requesting regulatory meetings.
- **China Strategy**: No near-term growth expectations, monitoring stimulus programs.
- **DHL Partnership**: Early positive feedback from clients, with integration efforts ongoing.


Cryoport, Inc. (CYRX) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue $41M (+10% YoY), with Life Sciences Services up 17%.
- **Strategic Win**: $195M DHL partnership to boost global reach & liquidity.
- **Pipeline Momentum**: 711 trials supported, 17+ filings & 4 approvals expected in 2025.
- **Margin Expansion**: Services gross margin improving; product demand stabilizing.
- **Shareholder Focus**: $100M+ net cash post-DHL close; buyback consideration.

**【CEO Opening Remarks】**
- Q1 2025 revenue from continuing operations: $41 million (+10% YoY), driven by 17% growth in Life Sciences Services.
- Key highlights:
  - Commercial cell/gene therapy revenue up 33% YoY, supporting 20 approved therapies.
  - BioStorage & BioServices revenue up 22.5% YoY.
  - Life Sciences Services now 56% of total revenue.
- Strategic partnership with DHL to enhance global reach, with CryoPDP divestiture expected Q2-Q3.
- FY25 revenue guidance reaffirmed: $165-172 million (+7.5% YoY midpoint).

**【CFO Financial Highlights】**
- Adjusted EBITDA improved YoY, with services gross margin expansion.
- Product revenue stabilized (+2% YoY), driven by North American demand.
- $195M enterprise value from DHL transaction to strengthen balance sheet.

**【Q&A Key Takeaways】**
- **Market Health**: 711 clinical trials supported (~70% of CGT pipeline), 17+ filings & 4 approvals expected in 2025.
- **Tariff Impact**: Mitigated via supply chain diversification; surcharges applied when unavoidable.
- **IntegriCell Progress**: Multiple contracts signed, onboarding programs in H1 2025.
- **DHL Synergies**: Enhanced EMEA/Asia Pac presence; Cryoport focuses on core services growth.
- **Shareholder Value**: $100M+ net cash post-DHL close; buyback authorization on table.

Cryoport (CYRX)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 commercial cell/gene therapy revenue up 37% Q4/20% full year, with 2025 guidance of $240-250 million.
- **Margin Expansion**: Q4 gross margin 45.8%, targeting 55% long-term. 2024 adjusted EBITDA loss narrowed to $22 million.
- **New Initiatives**: IntegriCell and HV3 system launches to drive 2025+ growth, with 23 expected BLA filings.
- **Stability in MVE**: Order patterns stabilizing, U.S. manufacturing mitigates China risks.


**【CEO Summary Section】**
- Cryoport reported full year 2024 revenue of $228.4 million, in line with expectations. Life Sciences Services revenue grew to 67% of total revenue, up from 62% in 2023, driven by 37% Q4 and 20% full year growth in commercial cell and gene therapy support.
- Launched IntegriCell cryopreservation facilities in Houston and Liege, and introduced the Cryoport Express HV3 cryogenic shipping system to improve patient access in underserved areas.
- Provided 2025 revenue guidance of $240-250 million, with a focus on achieving positive adjusted EBITDA and 55% long-term gross margin targets.

**【CFO Financial Commentary】**
- Q4 2024 gross margin improved to 45.8% (vs. 40.6% in 2023), with full year adjusted EBITDA loss narrowing to $22 million (from $30 million in 2023).
- Implemented cost management initiatives in the Product segment, reducing operating expenses and improving free cash flow generation.
- Targeting sequential margin improvements in 2025, with IntegriCell expected to contribute meaningfully by 2026.

**【Q&A Key Points】**
- **Commercial Revenue Growth**: 37% Q4 growth driven by multiple clients, not a single therapy. 2025 expects 23 BLA/MMA filings (3 already in Q1).
- **MVE Stability**: Order patterns showing stabilization, with modest 2025 growth expectations. U.S. manufacturing mitigates tariff risks.
- **Tariff Impact**: Passing through surcharges for steel/aluminum tariffs, no margin impact.
- **Clinical Trials**: Record 701 trials supported (81 in Phase III), up 26 from 2023. 2025 expects stronger new trial acquisition.
- **FDA Concerns**: No expected delays in approvals, with 3 filings in Q1 2025.


Cryoport (CYRX)-4 Mar 25-2024 Q4 Earnings call transcript

Cryoport (CYRX)-7 Nov 24-2024 Q3 Earnings call transcript

CryoPort (CYRX)-6 Aug 24-2024 Q2 Earnings call transcript

CryoPort (CYRX)-7 May 24-2024 Q1 Earnings call transcript

CryoPort (CYRX)-12 Mar 24-2023 Q4 Earnings call transcript

- **Revenue Surge**: Commercial revenue +54% YoY, Cryoport Systems +10%, bioservices +26%, driven by cell/gene therapy approvals.
- **Strategic Expansion**: Acquired Tec4med for AI logistics, launched U.K. hub, and expanded Integra-Cell capacity.
- **China Recovery**: MVE Biological Solutions stabilized at 4% of revenue, with recovery expected.
- **Financial Strength**: Non-GAAP EPS beat ($1.08 vs. $0.95), $6.2M gain from debt buybacks, and 45% MVE product gross margin.
- **Growth Catalysts**: 6 Q4 BLA filings, 20+ commercial therapies by 2024, and $36M buyback capacity.

**【CEO Summary Section】**
- **Revenue Growth**: Commercial revenue increased 54% YoY, Cryoport Systems grew 10% YoY, and bioservices revenue rose 26% YoY. 
- **Clinical Trials Expansion**: Added 27 net trials, bringing total to 670 (81 in Phase III). 6 BLAs/MAAs filed in Q3, with 5 more expected in Q4.
- **Strategic Acquisitions**: Acquired Tec4med Lifesciences for advanced AI-driven logistics monitoring. Launched U.K. logistics center to support European expansion.
- **China Market**: MVE Biological Solutions in China stabilized at 4% of total revenue, with expectations for recovery.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net income $420M, Non-GAAP EPS $1.08 (vs. $0.95 consensus). MVE product gross margin 45%, driving EBITDA and cash flow.
- **Cost Management**: Repurchased $12.5M of 2026 convertible debt, realizing $6.2M gain. $36M remaining under buyback program.
- **SG&A Growth**: 20% YoY increase due to investments in Integra-Cell, Cryoport Elite Shipper, and global infrastructure.

**【Q&A Key Highlights】**
- **Commercial Revenue Drivers**: Sarepta's product contributed meaningfully. 12 commercial therapies supported, with 6 more expected in 2024.
- **MVE Stabilization**: Order intake stabilized, with 70% global market share. China's impact limited to 4% of revenue.
- **Tec4med Integration**: Enhances real-time monitoring for pharma beyond cell/gene therapy, complementing SmartPack2.
- **Integra-Cell Progress**: Houston and Belgium facilities nearing validation, with strong client interest.
- **Cost Strategy**: Balancing growth investments (e.g., R&D up 21% sequentially) with EBITDA margin expansion potential.

Actual												-0.11	-0.15	-0.29	-1.32	-0.13	-0.16	-0.18	-5.46	-0.31	-0.23	-0.15	-0.24	-0.16	-0.42	-0.31	-1.31	-0.43	-1.62	-0.02	-0.42	-0.28	2.05	-0.18	-0.27
Forecast												-0.055	-0.1067	-0.1267	-0.039	-0.1822	-0.1213	-0.15	-0.1538	-0.2294	-0.1506	-0.1419	-0.205	-0.1927	-0.2371	-0.3181	-0.2833	-0.3453	-0.3965	-0.3092	-0.2928	-0.345	-0.2633	-0.2226	-0.2101
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-40.58%	-128.89%	-3284.62%	+28.65%	-31.90%	-20.00%	-3450.07%	-35.14%	-52.72%	-5.71%	-17.07%	+16.97%	-77.14%	+2.55%	-362.41%	-24.53%	-308.58%	+93.53%	-43.44%	+18.84%	+878.58%	+19.14%	-28.51%

CYRX

CYRX fundamentals

CYRX Q4 2025 Earnings

Earnings Call

You can ask Aime

CYRX

CYRX fundamentals

CYRX Q4 2025 Earnings

Earnings Call

CYRX Earnings Call Summary for Q4/20255:00 PM on Mar 3, 2026

CYRX Earnings Call Summary for Q3/20255:00 PM on Nov 4, 2025

CYRX Earnings Call Summary for Q2/20255:00 PM on Aug 5, 2025

CYRX Earnings Call Summary for Q1/20255:00 PM on May 7, 2025

CYRX Earnings Call Summary for Q4/20245:00 PM on Mar 4, 2025

You can ask Aime